Here is how Actinium Pharmaceuticals Inc (ATNM) stock might take investors finances to the next level

At the time of writing, Actinium Pharmaceuticals Inc [ATNM] stock is trading at $1.38, up 15.00%. An important factor to consider is whether the stock is rising or falling in short-term value. The ATNM shares have gain 4.55% over the last week, with a monthly amount drifted -10.97%, and not seem to be holding up well over a long-time horizon.

From an analyst’s perspective:

Actinium Pharmaceuticals Inc [AMEX: ATNM] stock has seen the most recent analyst activity on August 07, 2024, when B. Riley Securities downgraded its rating to a Neutral and also revised its price target to $2 from $16. Previously, Stephens started tracking the stock with Overweight rating on May 14, 2024, and set its price target to $25. On September 06, 2023, HSBC Securities initiated with a Buy rating and assigned a price target of $11.60 on the stock. William Blair downgraded its rating to a Mkt Perform. Cantor Fitzgerald initiated its recommendation with a Overweight and recommended $20 as its price target on September 08, 2022. B. Riley Securities started tracking with a Buy rating for this stock on August 25, 2022, and assigned it a price target of $16. In a note dated November 05, 2020, Alliance Global Partners initiated an Buy rating and provided a target price of $25 on this stock.

For the past year, the stock price of Actinium Pharmaceuticals Inc fluctuated between $1.03 and $10.24. Currently, Wall Street analysts expect the stock to reach $11.07 within the next 12 months. Actinium Pharmaceuticals Inc [AMEX: ATNM] shares were valued at $1.38 at the most recent close of the market. An investor can expect a potential return of 702.17% based on the average ATNM price forecast.

Analyzing the ATNM fundamentals

According to Actinium Pharmaceuticals Inc [AMEX:ATNM], the company’s sales were 0.00M for trailing twelve months, which represents an -100.00% plunge. To continue investigating profitability, this company’s Return on Assets is posted at -0.5, Equity is -0.96 and Total Capital is -0.61. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.05.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.2767 points at the first support level, and at 1.1733 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.4367, and for the 2nd resistance point, it is at 1.4933.

Ratios To Look Out For

It is important to note that Actinium Pharmaceuticals Inc [AMEX:ATNM] has a current ratio of 9.14. On the other hand, the Quick Ratio is 9.14, and the Cash Ratio is 8.95.

Related Posts